These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6102285)

  • 1. Malignant melanoma: an androgen-dependent tumour?
    Rampen FH; Mulder JH
    Lancet; 1980 Mar; 1(8168 Pt 1):562-4. PubMed ID: 6102285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex differences in survival from cutaneous melanoma.
    Rampen FH
    Int J Dermatol; 1984 Sep; 23(7):444-52. PubMed ID: 6386712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III).
    Balch CM; Soong SJ; Murad TM; Smith JW; Maddox WA; Durant JR
    J Clin Oncol; 1983 Feb; 1(2):126-34. PubMed ID: 6668496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant melanoma: sex differences in survival after evidence of distant metastasis.
    Rampen F
    Br J Cancer; 1980 Jul; 42(1):52-7. PubMed ID: 7426329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response.
    Vlaykova T; Talve L; Hahka-Kemppinen M; Hernberg M; Muhonen T; Collan Y; Pyrhönen S
    Oncology; 2002; 62(3):259-68. PubMed ID: 12065874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival after pulmonary metastasectomy in patients with malignant melanoma.
    Schuhan C; Muley T; Dienemann H; Pfannschmidt J
    Thorac Cardiovasc Surg; 2011 Apr; 59(3):158-62. PubMed ID: 21480136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.
    Monteagudo C; Martin JM; Jorda E; Llombart-Bosch A
    J Clin Pathol; 2007 Jun; 60(6):596-9. PubMed ID: 16522748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble ICAM-1 seems to be related to prognosis in malignant melanoma.
    Wollina U; Karte K; Hipler UC; Olbertz K
    J Eur Acad Dermatol Venereol; 1999 May; 12(3):264-6. PubMed ID: 10461652
    [No Abstract]   [Full Text] [Related]  

  • 9. Stage-IV melanoma and pulmonary metastases: factors predictive of survival.
    Neuman HB; Patel A; Hanlon C; Wolchok JD; Houghton AN; Coit DG
    Ann Surg Oncol; 2007 Oct; 14(10):2847-53. PubMed ID: 17680317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma.
    Petersen RP; Hanish SI; Haney JC; Miller CC; Burfeind WR; Tyler DS; Seigler HF; Wolfe W; D'Amico TA; Harpole DH
    J Thorac Cardiovasc Surg; 2007 Jan; 133(1):104-10. PubMed ID: 17198792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferation rates in human malignant melanoma: relationship to clinicopathological features and outcome.
    Laing JH; Wilson GD; Martindale CA
    Melanoma Res; 2003 Jun; 13(3):271-7. PubMed ID: 12777982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival with regional and distant metastases from cutaneous malignant melanoma.
    Roses DF; Karp NS; Oratz R; Dubin N; Harris MN; Speyer J; Boyd A; Golomb FM; Ransohoff J; Dugan M
    Surg Gynecol Obstet; 1991 Apr; 172(4):262-8. PubMed ID: 2006449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant melanoma: sex differences in response to chemotherapy?
    Rampen FH
    Eur J Cancer Clin Oncol; 1982 Jan; 18(1):107-10. PubMed ID: 7200889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Is surgical therapy of distant metastases of malignant melanoma worthwhile?].
    Göhl J; Meyer T; Haas C; Altendorf-Hofmann A; Hohenberger W
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():122-6. PubMed ID: 9101809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival after surgical resection of isolated pulmonary metastases from malignant melanoma.
    Andrews S; Robinson L; Cantor A; DeConti RC
    Cancer Control; 2006 Jul; 13(3):218-23. PubMed ID: 16885918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors.
    Tas F; Erturk K
    Melanoma Res; 2017 Apr; 27(2):134-139. PubMed ID: 28099368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue inhibitor of metalloproteinase-3 (TIMP3) expression decreases during melanoma progression and inhibits melanoma cell migration.
    Das AM; Bolkestein M; van der Klok T; Oude Ophuis CM; Vermeulen CE; Rens JA; Dinjens WN; Atmodimedjo PN; Verhoef C; Koljenović S; Smits R; Ten Hagen TL; Eggermont AM
    Eur J Cancer; 2016 Oct; 66():34-46. PubMed ID: 27522248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall survival and PD-L1 expression in metastasized malignant melanoma.
    Gadiot J; Hooijkaas AI; Kaiser AD; van Tinteren H; van Boven H; Blank C
    Cancer; 2011 May; 117(10):2192-201. PubMed ID: 21523733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Late metastasis in malignant melanoma of the skin].
    Landthaler M; Braun-Falco O; Schlamminger F; Schubert-Fritschle G
    Dtsch Med Wochenschr; 1989 Jul; 114(30):1149-52. PubMed ID: 2752919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry.
    Gassenmaier M; Keim U; Leiter U; Eigentler TK; Röcken M; Gesierich A; Moritz RKC; Heinzerling L; Tüting T; Wollina U; Garbe C
    J Am Acad Dermatol; 2019 May; 80(5):1299-1307.e7. PubMed ID: 30703453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.